FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327676480> ?p ?o ?g. }

• W4327676480 endingPage "1068" @default.
• W4327676480 startingPage "1053" @default.
• W4327676480 abstract "Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation. Claims data on persistence may be informative of real-world treatment outcome. This analysis described persistence and rates of remission of patients with psoriasis initiated on current biologics. Adults with psoriasis initiated (index date) on guselkumab, adalimumab, secukinumab, or ixekizumab between 07/13/2017 and 07/31/2020 were identified in the IBM MarketScan Databases. Discontinuation (or end of persistence) was defined as gaps in index biologic supply of more than twice the labelled dosing interval or mode days of supply (> 120 days for guselkumab and > 60 days for adalimumab, secukinumab, and ixekizumab). The proportion of patients reinitiating index therapy post-discontinuation and the proportion achieving remission (proxy definition: no claims for psoriasis-related treatment post-discontinuation among patients with ≥ 6 months of follow-up post-discontinuation) were assessed. There were 3408 patients in the guselkumab (mean age: 47.9 years old; female: 47.1%), 8017 in the adalimumab (47.4 years old; 54.1%), 6123 in the secukinumab (49.4 years old; 54.2%), and 3728 in the ixekizumab cohorts (49.1 years old; 50.3%). The median time to discontinuation was 26.2 months in the guselkumab cohort and 9.9, 12.4, and 12.5 months in adalimumab, secukinumab, and ixekizumab cohorts, respectively. Among those who discontinued index therapy, 22.9% in the guselkumab cohort and 21.1%, 31.9%, and 32.0% in the adalimumab, secukinumab, and ixekizumab cohorts reinitiated it. Remission rates were 17.2% in the guselkumab cohort and 12.4%, 10.5%, and 9.0% in adalimumab, secukinumab, and ixekizumab cohorts, respectively. Patients on guselkumab showed trends toward better persistence and higher remission rates relative to other biologics. Finding patients who may be in remission suggests potential disease modification with current agents." @default.
• W4327676480 created "2023-03-18" @default.
• W4327676480 creator A5000027607 @default.
• W4327676480 creator A5006964107 @default.
• W4327676480 creator A5019269759 @default.
• W4327676480 creator A5025682958 @default.
• W4327676480 creator A5033613047 @default.
• W4327676480 creator A5087398570 @default.
• W4327676480 creator A5090831117 @default.
• W4327676480 date "2023-03-16" @default.
• W4327676480 modified "2023-10-17" @default.
• W4327676480 title "Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA" @default.
• W4327676480 cites W1692288477 @default.
• W4327676480 cites W1874229874 @default.
• W4327676480 cites W1975463338 @default.
• W4327676480 cites W2017716530 @default.
• W4327676480 cites W2063627867 @default.
• W4327676480 cites W2144602414 @default.
• W4327676480 cites W2158181654 @default.
• W4327676480 cites W2170072431 @default.
• W4327676480 cites W2590069344 @default.
• W4327676480 cites W2613498155 @default.
• W4327676480 cites W2769068226 @default.
• W4327676480 cites W2771625138 @default.
• W4327676480 cites W2781078917 @default.
• W4327676480 cites W2809143647 @default.
• W4327676480 cites W2912058252 @default.
• W4327676480 cites W2942628741 @default.
• W4327676480 cites W2963643921 @default.
• W4327676480 cites W2980330075 @default.
• W4327676480 cites W2983492325 @default.
• W4327676480 cites W3028355101 @default.
• W4327676480 cites W3130492453 @default.
• W4327676480 cites W3139309195 @default.
• W4327676480 cites W3143775625 @default.
• W4327676480 cites W3179952304 @default.
• W4327676480 cites W3207458298 @default.
• W4327676480 cites W4205839940 @default.
• W4327676480 cites W4210942513 @default.
• W4327676480 cites W4214515549 @default.
• W4327676480 cites W4220927294 @default.
• W4327676480 cites W4284675502 @default.
• W4327676480 cites W617829016 @default.
• W4327676480 doi "https://doi.org/10.1007/s13555-023-00910-6" @default.
• W4327676480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36929120" @default.
• W4327676480 hasPublicationYear "2023" @default.
• W4327676480 type Work @default.
• W4327676480 citedByCount "3" @default.
• W4327676480 countsByYear W43276764802023 @default.
• W4327676480 crossrefType "journal-article" @default.
• W4327676480 hasAuthorship W4327676480A5000027607 @default.
• W4327676480 hasAuthorship W4327676480A5006964107 @default.
• W4327676480 hasAuthorship W4327676480A5019269759 @default.
• W4327676480 hasAuthorship W4327676480A5025682958 @default.
• W4327676480 hasAuthorship W4327676480A5033613047 @default.
• W4327676480 hasAuthorship W4327676480A5087398570 @default.
• W4327676480 hasAuthorship W4327676480A5090831117 @default.
• W4327676480 hasBestOaLocation W43276764801 @default.
• W4327676480 hasConcept C126322002 @default.
• W4327676480 hasConcept C16005928 @default.
• W4327676480 hasConcept C187212893 @default.
• W4327676480 hasConcept C2776260265 @default.
• W4327676480 hasConcept C2777011040 @default.
• W4327676480 hasConcept C2777575956 @default.
• W4327676480 hasConcept C2778715236 @default.
• W4327676480 hasConcept C2778975655 @default.
• W4327676480 hasConcept C2779745271 @default.
• W4327676480 hasConcept C2779786854 @default.
• W4327676480 hasConcept C2780132546 @default.
• W4327676480 hasConcept C2780564577 @default.
• W4327676480 hasConcept C71924100 @default.
• W4327676480 hasConcept C72563966 @default.
• W4327676480 hasConceptScore W4327676480C126322002 @default.
• W4327676480 hasConceptScore W4327676480C16005928 @default.
• W4327676480 hasConceptScore W4327676480C187212893 @default.
• W4327676480 hasConceptScore W4327676480C2776260265 @default.
• W4327676480 hasConceptScore W4327676480C2777011040 @default.
• W4327676480 hasConceptScore W4327676480C2777575956 @default.
• W4327676480 hasConceptScore W4327676480C2778715236 @default.
• W4327676480 hasConceptScore W4327676480C2778975655 @default.
• W4327676480 hasConceptScore W4327676480C2779745271 @default.
• W4327676480 hasConceptScore W4327676480C2779786854 @default.
• W4327676480 hasConceptScore W4327676480C2780132546 @default.
• W4327676480 hasConceptScore W4327676480C2780564577 @default.
• W4327676480 hasConceptScore W4327676480C71924100 @default.
• W4327676480 hasConceptScore W4327676480C72563966 @default.
• W4327676480 hasFunder F4320317188 @default.
• W4327676480 hasIssue "4" @default.
• W4327676480 hasLocation W43276764801 @default.
• W4327676480 hasLocation W43276764802 @default.
• W4327676480 hasLocation W43276764803 @default.
• W4327676480 hasOpenAccess W4327676480 @default.
• W4327676480 hasPrimaryLocation W43276764801 @default.
• W4327676480 hasRelatedWork W1970925217 @default.
• W4327676480 hasRelatedWork W2783970348 @default.
• W4327676480 hasRelatedWork W2915020735 @default.
• W4327676480 hasRelatedWork W3025568817 @default.
• W4327676480 hasRelatedWork W3028355101 @default.

• next